• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

byDavid XiangandKiera Liblik
January 10, 2023
in Chronic Disease, Neurology, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo.

2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to patients and the healthcare system. Lecanemab is a humanized monoclonal antibody that binds to soluble amyloid-beta protofibrils. Previously, a phase 2b trial showed no significant difference between lecanemab and placebo at 12 months in patients with Alzheimer’s disease. Though, analyses at 18 months showed less clinical decline on some measures than placebo. However, there is a gap in knowledge as to understanding the safety and efficacy of lecanemab in patients with early Alzheimer’s disease. Overall, this study found that in persons with early Alzheimer’s disease, lecanemab was associated with reduced brain amyloid levels as well as moderately less decline in clinical measures of cognition and function than placebo at 18 months. Notably, lecanemab was associated with an increased number of adverse events. This study was limited by short follow-up time (18 months), having a dropout rate of 17.2%, and some participants and investigators being aware of the trial-group assignments. Nevertheless, these findings are significant, as they demonstrate that lecanemab may provide cognitive and functional benefits in patients with early Alzheimer’s disease.

Click to read the study in NEJM

Relevant Reading: Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab

In-Depth [randomized controlled trial]: This multicenter, double-blind, placebo-controlled, parallel-group trial was conducted to determine the efficacy of lecanemab in treating patients with early Alzheimer’s disease. Patients who were between 50 to 90 years of age with mild cognitive impairment due to Alzheimer’s were eligible for the study. All participants also had objective impairment in episodic memory as indicated by at least one standard deviation below the age-adjusted mean in the Wechsler Memory Scale IV–Logical Memory II. Patients who did not fit these inclusion criteria were excluded from the study. Patients were followed for a total of 18 months. The primary outcome measured was the change in the score on the Clinical Dementia Rating (CDR)–Sum of Boxes (CDR-SB)18 from baseline to 18 months. Outcomes in the primary analysis were assessed via efficacy analyses in the modified intention to treat population. Based on the primary analysis, the adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, -0.45; 95% confidence interval [CI], -0.67 to -0.23; p<0.001). In a sub-study involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo (difference, -59.1 centiloids; 95% CI, -62.6 to -55.6). However, lecanemab resulted in infusion-related reactions in 26.4% of participants and amyloid-related imaging abnormalities with edema or effusions in 12.6% of participants. Overall, this study demonstrates that lecanemab was associated with reduced markers of amyloid in early Alzheimer’s disease and resulted in less decline in cognitive and functional measures than placebo at 18 months but was associated with significant adverse effects.

RELATED REPORTS

Stroke may be associated with sleep disturbances in adults

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer'sAlzheimer’s diseaseamyloid markerschronic diseaseEarly alzheimer'slecanemabneurologypsychiatry
Previous Post

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

Next Post

Higher rate of adverse events following abortion induced by mifepristone-misoprostol than procedurally

RelatedReports

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Stroke may be associated with sleep disturbances in adults

March 25, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

March 20, 2023
Psychiatric conditions less likely to be granted physician-assisted suicide
Chronic Disease

Dementia is associated with high rates of sleep-related breathing disorders

March 20, 2023
Next Post
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

Higher rate of adverse events following abortion induced by mifepristone-misoprostol than procedurally

No benefit of erlotinib in combined hepatocellular carcinoma treatment

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

Pediatric DKA associated with recent acute care visits

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options